Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of hepatitis C virus genotype 2a replicon variants with reduced susceptibility to ribavirin.

Antiviral research - 1 Mar 2010

Hmwe Su Su, Aizaki Hideki, Date Tomoko, Murakami Kyoko, Ishii Koji, Miyamura Tatsuo, Koike Kazuhiko, Wakita Takaji, Suzuki Tetsuro

Abstract excerpt

Ribavirin (RBV), a nucleoside analogue, is used in the treatment of hepatitis C virus (HCV) infection in combination with interferons. However, potential mechanisms of RBV resistance during HCV replication remain poorly understood. Serial passage of cells harboring HCV genotype 2a replicon in the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Serial Passage
Share to Amino Acid Substitution
Share to Antiviral Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepacivirus

Share to Mutagenesis, Site-Directed

Share to Replicon

Share to Ribavirin

Share to Viral Nonstructural Proteins

Source

Identifiers

PMID: 20043953
DOI: 10.1016/j.antiviral.2009.12.008

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20043953-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of hepatitis C virus genotype 2a replicon variants with reduced susceptibility to ribavirin.PMID 20043953Read ↗

HCV Replicon Systems: Workhorses of Drug Discovery and Resistance.Semantic proximity Read ↗

Studies on hepatitis C virus resistance to inhibitors in replicon systems.Semantic proximity Read ↗

Establishment of hepatitis C virus replicon cell lines possessing interferon-resistant phenotype.Semantic proximity Read ↗

HCV antiviral resistance: the impact of in vitro studies on the development of antiviral agents targeting the viral NS5B polymerase.Semantic proximity Read ↗

Mutations conferring resistance to SCH6, a novel hepatitis C virus NS3/4A protease inhibitor. Reduced RNA replication fitness and partial rescue by second-site mutations.Semantic proximity Read ↗

Identification of a novel replication-competent hepatitis C virus variant that confers the sofosbuvir resistance.Semantic proximity Read ↗

Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system.Semantic proximity Read ↗

Hepatitis C virus genotype 5a subgenomic replicons for evaluation of direct-acting antiviral agents.Semantic proximity Read ↗

Ribavirin resistance in hepatitis C virus replicon-containing cell lines conferred by changes in the cell line or mutations in the replicon RNA.Semantic proximity Read ↗

Establishment of robust HCV genotype 4d, 5a, and 6a replicon systems.Semantic proximity Read ↗

Identification and characterization of mutations conferring resistance to an HCV RNA-dependent RNA polymerase inhibitor in vitro.Semantic proximity Read ↗

Development of a replicon-based phenotypic assay for assessing the drug susceptibilities of HCV NS3 protease genes from clinical isolatesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.